Search hospitals > Virginia > Fairfax
Lysosomal and Rare Disorders Research and Treatment Center, Inc
Claim this profileFairfax, Virginia 22030
Conducts research for Fabry Disease
Conducts research for Gaucher Disease
Conducts research for Pompe Disease
Conducts research for Primary Immunodeficiency
Conducts research for Immune Deficiency Syndrome
17 reported clinical trials
1 medical researcher
Summary
Lysosomal and Rare Disorders Research and Treatment Center, Inc is a medical facility located in Fairfax, Virginia. This center is recognized for care of Fabry Disease, Gaucher Disease, Pompe Disease, Primary Immunodeficiency, Immune Deficiency Syndrome and other specialties. Lysosomal and Rare Disorders Research and Treatment Center, Inc is involved with conducting 17 clinical trials across 15 conditions. There are 1 research doctors associated with this hospital, such as Ozlem Goker-Alpan, MD.Top PIs
Clinical Trials running at Lysosomal and Rare Disorders Research and Treatment Center, Inc
Fabry Disease
Gaucher Disease
Pompe Disease
Kidney Disease
Disease
Migalastat
for Fabry Disease
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
Recruiting4 awards Phase 38 criteria
Shorter Infusion of Fabrazyme
for Fabry Disease
This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
Recruiting3 awards Phase 46 criteria
Venglustat
for Fabry Disease
This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventricular mass index (LVMI) in adult participants with Fabry disease and left ventricular hypertrophy. * Study visits will take place approximately every 3 to 6 months * Participants who complete the randomized period may continue to the long-term extension (LTE) to receive venglustat for up to additional 34 months with the total study duration up to 4.4 years maximum.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Lysosomal and Rare Disorders Research and Treatment Center, Inc?
Lysosomal and Rare Disorders Research and Treatment Center, Inc is a medical facility located in Fairfax, Virginia. This center is recognized for care of Fabry Disease, Gaucher Disease, Pompe Disease, Primary Immunodeficiency, Immune Deficiency Syndrome and other specialties. Lysosomal and Rare Disorders Research and Treatment Center, Inc is involved with conducting 17 clinical trials across 15 conditions. There are 1 research doctors associated with this hospital, such as Ozlem Goker-Alpan, MD.